TABLE 2.

Prevalence of resistance to other antimicrobials in Enterobacter cloacae by β-lactamase phenotype

Strain characteristics and country or locale	No. of strains	Percentage of strains not susceptible toa:
		TIM	TZP	FEP	CIP	GEN	SXT
Ceftriaxone and ceftazidime susceptible (MICs of ≤1 and ≤2, respectively)
Australia	113	6	0	0	1	0	3
Hong Kong	19	30	0	0	0	0	5
Japan	64	11	0	0	2	0	2
Mainland China	14	13	0	0	7	0	7
Philippines	42	12	0	0	5	0	10
Singapore	13	8	0	0	0	0	8
South Africa	30	17	0	0	0	0	3
Taiwan	28	14	0	0	4	4	14
Total	323	11	0	0	2	<1	5
Ceftriaxone MIC of >1 and ceftazidime MIC of >2
ESBL negative
Australia	58	95	76	0	3	3	10
Hong Kong	14	100	79	7	29	14	29
Japan	32	100	81	9	28	25	28
Mainland China	9	100	89	0	67	67	44
Philippines	19	95	79	5	53	42	53
Singapore	2	100	50	0	0	0	50
South Africa	13	100	92	15	15	23	23
Taiwan	20	80	60	5	20	40	40
Total	167	95	77	5	22	22	27
ESBL positive
Australia	7	100	29	0	0	100	86
Hong Kong	2	100	100	0	100	100	100
Japan	3	100	33	67	33	0	33
Mainland China	14	100	57	64	79	86	71
Philippines	33	91	24	0	33	48	91
Singapore	12	92	25	25	50	58	83
South Africa	11	82	18	9	18	91	91
Taiwan	11	91	36	18	18	91	91
Total	93	92	32	18	38	69	85

^aAbbreviations: TIM, ticarcillin-clavulanate; TZP, piperacillin-tazobactam; FEP, cefepime; CIP, ciprofloxacin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole.